Jennifer J. Larsen

Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019

Ravindra Ganesh, Lindsey M. Philpot, Dennis M. Bierle et al. · The Journal of Infectious Diseases · 2021 · 102 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +10

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19

Raymund R. Razonable, Nicole C.E. Aloia, Ryan J. Anderson et al. · Mayo Clinic Proceedings · 2021 · 54 citations · Full text

Pharmacy, Health Informatics, Infectious Diseases +17

Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

Ravindra Ganesh, Colin Pawlowski, John C. O’Horo et al. · Journal of Clinical Investigation · 2021 · 46 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +7

Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch

Raymund R. Razonable, John C. O’Horo, Sara N. Hanson et al. · The Journal of Infectious Diseases · 2022 · 37 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

The IPCS Collaborative Study on Neurobehavioral Screening Methods: V. Results of chemical testing. Steering Group.

Virginia C. Moser, G.C. Becking, Valentina Cuomo et al. · PubMed · 1997 · 31 citations

Social Sciences, Psychology, Toxicology +14